Peptide Half-Life Chart

Compare half-lives across all peptides. Longer half-lives allow less frequent dosing. Click any peptide to open its calculator.

~24+ hours (estimated from animal models, duration of effect up to 28 days)

Lanreotide (Somatuline Depot)

~23-30 days (depot formulation)

~12.7 days (IV, rat)

~9 days (220 hours)

~5 hours plasma (functional tissue activity persists 7-10 days)

TRT (Testosterone Replacement Therapy)

~8 days (testosterone cypionate IM)

~7 days (semaglutide component ~158h; cagrilintide component ~184h)

MIF-1 (Pro-Leu-Gly-NH2)

~2 hours (functional CNS duration); plasma stability ~5 days

Dulaglutide (Trulicity)

~5 days (120 hours)

Pemvidutide (ALT-801)

~4-6 days (estimated)

Romiplostim (Nplate)

~3.5 days (median)

~48-72 hours (PEGylated); native MGF: ~5-7 minutes

HCG (Human Chorionic Gonadotropin)

~23 hours (functional, animal data)

~15 hours (implant)

Pasireotide (Signifor)

~12 hours (subcutaneous)

Bromantane (Ladasten)

~7-8 min free plasma; ~7-8 hours carrier-bound (functional duration)

NA-Selank Amidate

~2-3 min (plasma); functional effects persist 6-8 hours via downstream gene expression

~6 hours (topical; no systemic PK data)

~3-8 hours (terminal, varies by clearance)

MK-677 (Ibutamoren)

~5 hours (IGF-1 elevation lasts ~24h)

Wolverine Stack (BPC-157 + TB-500)

~30 min plasma (functional anti-inflammatory activity persists 4-6 hours)

~4-6 hours (estimated from murine PK)

~4-6 hours (estimated oral)

Cyclic Glycine-Proline (cGP)

~4-6 hours (estimated; enzymatically stable cyclic dipeptide)

FGL (FG Loop Peptide)

~4-6 hours (subcutaneous administration)

Ziconotide (Prialt)

~4.6 hours (CSF); ~1.3 hours (serum)

~30 min plasma (functional tissue activity ~4 hours)

SS-31 (Elamipretide)

KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)

Varies by component (15 min–4 hours)

~30 min in mice (IP); >4 hours in rats (IP). Human half-life unknown.

~2-6 hours (estimated, polypeptide complex)

Enfuvirtide (Fuzeon)

GLOW Blend (BPC-157 + TB-500 + GHK-Cu)

Varies by component (~1-6 hours)

~0.5-2 hours (estimated, tetrapeptide)

~0.5-2 hours (estimated, ultrashort peptide)

Defensin (HNP-1)

~3-4 hours (estimated, based on peptide clearance kinetics)

Desmopressin (DDAVP)

2.5-3.5 hours (subcutaneous/IV)

~2-4 hours (estimated)

~3 min (IV), central effects last 2-4 hours (intranasal)

~2-4 hours (estimated, D-retro-inverso form may extend effective duration)

Adipotide (FTPP)

~2-4 hours (estimated)

~2-4 hours (estimated from in vitro decay; no formal human PK studies)

~2-4 hours (estimated, polypeptide complex)

~2-4 hours (estimated, short peptide complex)

~0.5-1 hour (estimated from tetrapeptide class)

Leuprolide (Lupron)

~3 hours (terminal elimination after SC/IV; depot formulations sustain release over 1-6 months)

~2-4 hours (estimated, topical peptide)

Lactoferricin B (LfcinB)

~2-4 hours (estimated; rapid proteolytic degradation in vivo)

HGH (Somatropin)

~10 min (plasma); 2-3 hours (intracellular)

AICAR (Acadesine)

~2-3 hours (plasma)

Larazotide (AT-1001)

Luminal activity ~1-4 hours (not systemically absorbed)

~1-4 hours (estimated, short peptide complex)

Eptifibatide (Integrilin)

Exenatide (Byetta / Bydureon)

~2.4 hours (Byetta IR); ~2 weeks sustained release (Bydureon ER)

Thymosin Alpha 1

Thymosin Beta-4

~2 hours (IV)

~1-3 hours (estimated, polypeptide complex)

~1-3 hours (estimated; no formal PK studies published)

Teduglutide (Gattex/Revestive)

~2 hours (1.3h in SBS patients; range 0.9-3h depending on body weight)

Octreotide (Sandostatin)

~1.7-1.9 hours (subcutaneous)

Atosiban (Tractocile)

Initial: ~13 min (tα), Terminal: ~1.7 hours (tβ)

~1-2 hours (plasma)

Follistatin-344

~1-2 hours (estimated)

Icatibant (Firazyr)

~30 minutes (IV), ~60-90 minutes (SC)

Calcitonin (Miacalcin)

~1 hour (58-64 minutes)

Variable (multi-compound blend)

~3+ hours (estimated, plasma)

Unknown (topical peptide — no systemic PK data)

Unknown (topical peptide — no systemic PK data available)

Unknown (oral peptide complex, no published PK data)

Unknown (oral peptide complex)

Unknown (topical peptide — no systemic PK data available)

Unknown (topical peptide — no systemic PK data available)

Linaclotide (Linzess)

Not measurable systemically — acts locally in the intestinal lumen and is degraded within the GI tract

Plecanatide (Trulance)

Not measurable (minimal systemic absorption)

~15-30 seconds (rapid degradation by kininases)

Pramlintide (Symlin)

Bivalirudin (Angiomax)

25 minutes (normal renal function); 34-57 minutes (moderate-severe renal impairment); 3.5 hours (dialysis patients)

Carbetocin (Duratocin/Pabal)

33-55 minutes (IV: ~33 min, IM: ~55 min)

CJC-1295 (No DAC)

CJC-1295 + Ipamorelin

~30 minutes (plasma)

~0.5 hours (estimated; no formal PK studies published)

Orexin (Hypocretin)

~30 minutes (Orexin-A); ~5 minutes (Orexin-B)

~20-35 minutes (plasma); variable CNS half-life

Neuropeptide Y (NPY)

~20-30 minutes (plasma)

~15-30 minutes (estimated)

~15-30 minutes (estimated, short-chain tetrapeptide)

~15-30 minutes (estimated from tripeptide class)

~20 minutes (plasma)

Alpha-MSH (α-Melanocyte-Stimulating Hormone)

~20 minutes (rapid proteolytic degradation)

Nesiritide (Natrecor)

Omberacetam (Noopept)

~15-20 min (plasma); active metabolite CPG persists longer

ACTH (Cosyntropin/Cortrosyn)

Vasopressin (Vasostrict)

10-20 minutes (IV)

Glucagon (GlucaGen)

8-18 minutes (IV), ~26 minutes (IM), ~35-45 minutes (SC/intranasal)

~10 minutes (serum half-life)

NA-Semax Amidate

~5-10 min (intranasal)

CGRP (Calcitonin Gene-Related Peptide)

~6.9 minutes (alpha-CGRP); rapid renal and hepatic clearance

MGF (Mechano Growth Factor)

~6 minutes in vitro (native peptide; rapid serum degradation)

~5 minutes (native peptide, rapid ACE2/neprilysin degradation in plasma)

Endomorphin-1 & Endomorphin-2

~2-8 minutes (plasma); rapid enzymatic degradation in vivo

~4 min (IV), ~30 min (SC)

Cholecystokinin (CCK-8)

2-5 minutes (IV)

2-4 min (IV), ~10-40 min (SC)

~2-3 min (IV)

~2-3 min (IV)

Somatostatin (SST-14 and SST-28)

~1-3 minutes (IV); SST-28 ~2-3x longer than SST-14

VIP (Vasoactive Intestinal Peptide)

~1-2 minutes (plasma)

~1-2 minutes (rapid enzymatic degradation)

~1.3 minutes (plasma); 45 minutes terminal elimination (IV)